Arvinas Inc
ARVN7.556USD
+0.136+1.84%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
551.62MCap. mercado
PérdidaP/E TTM
Más Datos de Arvinas Inc Compañía
Arvinas, Inc. is a clinical-stage biotechnology company. The Company, through its PROteolysis Targeting Chimera (PROTAC) protein degrader platform, is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. It is progressing multiple investigational drugs through clinical development programs, including vepdegestrant, ARV-393 and ARV-102. Vepdegestrant is an investigational orally bioavailable PROTAC protein degrader designed to target and degrade the ER for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. It is co-developing vepdegestrant with Pfizer. ARV-393 is an investigational, orally bioavailable PROTAC designed to degrade BCL6, a transcriptional repressor and a key regulator of normal B-cell maturation and differentiation processes. ARV-102 is in development to treat neurodegenerative diseases.
Información de la empresa
Símbolo de cotizaciónARVN
Nombre de la empresaArvinas Inc
Fecha de salida a bolsaSep 27, 2018
Director ejecutivoDr. John G. Houston, Ph.D.
Número de empleados430
Tipo de seguridadOrdinary Share
Fin del año fiscalSep 27
Dirección5 Science Park
CiudadNEW HAVEN
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal06511-1966
Teléfono12035351456
Sitio Webhttps://www.arvinas.com/
Símbolo de cotizaciónARVN
Fecha de salida a bolsaSep 27, 2018
Director ejecutivoDr. John G. Houston, Ph.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. John G. Houston, Ph.D.
Dr. John G. Houston, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
912.27K
-7.52%
Dr. Angela Cacace, Ph.D.
Dr. Angela Cacace, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
74.86K
-3.34%
Dr. Noah Berkowitz, M.D., Ph.D.
Dr. Noah Berkowitz, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
66.81K
+827.20%
Ms. Leslie V. Norwalk, Esq.
Ms. Leslie V. Norwalk, Esq.
Independent Director
Independent Director
26.05K
+159.93%
Mr. Everett V. Cunningham
Mr. Everett V. Cunningham
Independent Director
Independent Director
26.05K
+159.93%
Dr. Sunil Agarwal, M.D.
Dr. Sunil Agarwal, M.D.
Independent Director
Independent Director
24.67K
+185.35%
Mr. Edward (Ted) Kennedy, Jr.
Mr. Edward (Ted) Kennedy, Jr.
Independent Director
Independent Director
--
--
Dr. Laurie Smaldone Alsup, M.D.
Dr. Laurie Smaldone Alsup, M.D.
Independent Director
Independent Director
--
--
Mr. Briggs W. Morrison, M.D.
Mr. Briggs W. Morrison, M.D.
Lead Independent Director
Lead Independent Director
--
--
Mr. Andrew Saik
Mr. Andrew Saik
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. John G. Houston, Ph.D.
Dr. John G. Houston, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
912.27K
-7.52%
Dr. Angela Cacace, Ph.D.
Dr. Angela Cacace, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
74.86K
-3.34%
Dr. Noah Berkowitz, M.D., Ph.D.
Dr. Noah Berkowitz, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
66.81K
+827.20%
Ms. Leslie V. Norwalk, Esq.
Ms. Leslie V. Norwalk, Esq.
Independent Director
Independent Director
26.05K
+159.93%
Mr. Everett V. Cunningham
Mr. Everett V. Cunningham
Independent Director
Independent Director
26.05K
+159.93%
Dr. Sunil Agarwal, M.D.
Dr. Sunil Agarwal, M.D.
Independent Director
Independent Director
24.67K
+185.35%
Desglose de ingresos
FY2025Q1
FY2024
FY2023
Sin datos
Por regiónUSD
Nombre
Ganancia
Proporción
United States
188.80M
0.00%
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: dom., 27 de jul
Actualizado: dom., 27 de jul
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
The Vanguard Group, Inc.
11.44%
BlackRock Institutional Trust Company, N.A.
6.90%
Citadel Advisors LLC
5.31%
T. Rowe Price Associates, Inc.
5.14%
Pfizer Inc
4.74%
Other
66.47%
Accionistas
Accionistas
Proporción
The Vanguard Group, Inc.
11.44%
BlackRock Institutional Trust Company, N.A.
6.90%
Citadel Advisors LLC
5.31%
T. Rowe Price Associates, Inc.
5.14%
Pfizer Inc
4.74%
Other
66.47%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
36.14%
Hedge Fund
24.67%
Investment Advisor/Hedge Fund
17.48%
Venture Capital
6.80%
Corporation
4.74%
Research Firm
3.41%
Individual Investor
2.23%
Sovereign Wealth Fund
1.70%
Pension Fund
0.37%
Other
2.45%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
503
71.52M
97.99%
-18.05M
2025Q1
525
68.48M
93.89%
-22.67M
2024Q4
505
80.31M
116.78%
-4.24M
2024Q3
496
79.95M
116.50%
-140.10K
2024Q2
489
78.26M
114.11%
+1.71M
2024Q1
494
75.44M
110.48%
+3.48M
2023Q4
497
68.16M
100.81%
+12.55M
2023Q3
472
52.04M
94.71%
-3.94M
2023Q2
473
53.77M
100.76%
-3.55M
2023Q1
475
55.60M
104.22%
-4.17M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
The Vanguard Group, Inc.
8.35M
11.44%
+1.30M
+18.43%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
5.04M
6.9%
-246.30K
-4.66%
Mar 31, 2025
Citadel Advisors LLC
3.88M
5.31%
+395.72K
+11.37%
Mar 31, 2025
T. Rowe Price Associates, Inc.
3.75M
5.14%
-273.88K
-6.81%
Mar 31, 2025
Pfizer Inc
3.46M
4.74%
--
--
Mar 31, 2025
RTW Investments L.P.
3.33M
4.57%
--
--
Mar 31, 2025
Logos Global Management LP
3.30M
4.52%
+3.30M
--
Jun 10, 2025
Opaleye Management Inc.
1.98M
2.71%
+350.00K
+21.54%
Mar 31, 2025
State Street Global Advisors (US)
1.90M
2.6%
+259.14K
+15.83%
Mar 31, 2025
Alyeska Investment Group, L.P.
1.80M
2.47%
+1.80M
--
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
SPDR S&P Pharmaceuticals ETF
1.09%
Virtus LifeSci Biotech Clinical Trials ETF
0.88%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
0.77%
Invesco NASDAQ Future Gen 200 ETF
0.46%
Tema Oncology ETF
0.41%
Federated Hermes MDT Small Cap Core ETF
0.3%
iShares U.S. Pharmaceuticals ETF
0.25%
Zacks Small/Mid Cap ETF
0.18%
JPMorgan Fundamental Data Science Small Core ETF
0.15%
Tema Neuroscience and Mental Health ETF
0.15%
Ver más
SPDR S&P Pharmaceuticals ETF
Proporción1.09%
Virtus LifeSci Biotech Clinical Trials ETF
Proporción0.88%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proporción0.77%
Invesco NASDAQ Future Gen 200 ETF
Proporción0.46%
Tema Oncology ETF
Proporción0.41%
Federated Hermes MDT Small Cap Core ETF
Proporción0.3%
iShares U.S. Pharmaceuticals ETF
Proporción0.25%
Zacks Small/Mid Cap ETF
Proporción0.18%
JPMorgan Fundamental Data Science Small Core ETF
Proporción0.15%
Tema Neuroscience and Mental Health ETF
Proporción0.15%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
